AI assistant
REPLIGEN CORP — Director's Dealing 2020
Mar 5, 2020
30826_dirs_2020-03-05_645ac6d9-b4e5-4afb-b332-3cc44f1e80bf.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: REPLIGEN CORP (RGEN)
CIK: 0000730272
Period of Report: 2020-03-03
Reporting Person: KURIYEL RALF (Senior VP, R&D)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-03-03 | Common Stock | S | 450 | $88.35 | Disposed | 29079 | Direct |
| 2020-03-04 | Common Stock | S | 650 | $90.08 | Disposed | 28429 | Direct |
| 2020-03-04 | Common Stock | S | 1905 | $90.99 | Disposed | 26524 | Direct |
Footnotes
F1: Sale of shares in the open market to cover tax liability resulting from the release of restricted stock units.
F2: $88.35 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.31 to $88.47, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3: $90.99 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.83 to $91.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.